N-aralkylpyroglutamides of substituted bispidine were prepared and evaluated for their ability to inhibit collagen induced platelet aggregation, both in vivo and in vitro. Some compounds showed high anti-platelet efficacy (in vitro) of which six inhibited both collagen as well as U46619 induced platelet aggregation with concentration dependent anti-platelet efficacy through dual mechanism. In particular
制备了取代的联
吡啶的N-芳烷基焦谷
氨酰胺,并在体内和体外评估其抑制胶原诱导的血小板聚集的能力。一些化合物显示出很高的抗血小板功效(体外),其中有六种化合物通过双重机制抑制
胶原蛋白以及U46619诱导的血小板凝集,并具有浓度依赖性的抗血小板功效。特别地,该化合物4 Ĵ提供针对显著保护胶原诱导
肾上腺素肺血栓栓塞症,以及
氯化
铁诱导的动脉血栓形成,而不影响在小鼠出血倾向。因此,本研究表明化合物4 j 显示出显着的抗血栓形成功效,比
阿司匹林和
氯吡格雷好得多。